Cash-Rich Ipsen Opens Up Checkbook For 2019
2019 looks set to be a transformative year for Ipsen, with a pivotal clinical trial readout expected for combination Cabometyx in frontline kidney and liver cancer, and a series of deals promised by the company to investors looking for reassurance over long-term growth. CEO David Meek spoke to Scrip.
You may also be interested in...
Pfizer Well-Placed To Lead First-Line Advanced RCC Market
Two successful Phase III studies of Inlyta in combination with two distinct immunotherapies, including its own, Merck KGaA-partnered Bavencio, puts Pfizer in a very strong position in the advanced kidney cancer market.
Merck & Co.’s Keytruda/Inlyta Combo Invades Kidney Cancer Territory
Merck & Co.’s IO powerhouse Keytruda has trumped Bavencio’s recent Inlyta combo PFS win in kidney cancer, with a OS and PFS combo hit of its own. But the field is getting increasingly crowded.
Pfizer/Merck KgAA Move Fast With Bid For Bavencio/Inlyta In Kidney Cancer Market
Study of PD-L1/TKI combo succeeded in an all comers population across risk groups, which could be differentiating, for a while.